Celltrion Healthcare starts to sell biosimilar ‘Herzuma’ in Japan

Published: 2018-08-27 16:31:00
Updated: 2018-08-27 17:51:43

Celltrion Healthcare announced on the 23rd that they would start to sell the antibody biosimilar ‘Herzuma(generic name: trastuzumab)’ this month in Japan. The Japanese Ministry of Health, Labour and Welfare approved ‘Herzuma’ sales last March.

The Japanese trastuzumab market is approximately wor...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.